How has pharmacovigilance evolved to address the complexities of modern therapies? Initially focused on simpler medicines, pharmacovigilance now tackles sophisticated modalities like CAR T-cell and gene therapies. This session will explore the benefits of early risk profiling for CAR T-cell therapies and the harmonization of pharmacovigilance guidance for next-generation biologic therapies. The session will feature a panel discussion with industry and regulatory experts, who will discuss the challenges of maintaining an effective pharmacovigilance system capable of handling the complexities of new therapeutic advancements.
We are dedicated to uniting evidence and access for biopharma. Fill out the form to get in touch with our team and learn more.
Subscribe Now
Subscribe Now
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
President & Chief Executive Officer
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.